Tradestie Institutional Equity Comparison Engine
KROS vs LYRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
KROS Overall Edge
KROS Captures Institutional Edge (4โ0 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Keros Therapeutics, Inc. Common Stock (KROS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, KROS trades at 48.8x Forward P/E with -172.4% operating margin (+180.5% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, KROS sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
KROS
KROS 48.8x vs LYRA N/M Fwd P/E
Growth & Margin Winner
KROS
Op Margin -172.4% vs -25032.0% ยท YoY +180.5% vs -87.2%
Momentum & Technical Winner
KROS
1Y -35.3% vs -94.3% ยท 52W Pos 16% vs 1%
Options & Structure Winner
KROS
CONSOLIDATION (10th %ile IV) vs UNCLASSIFIED (N/A IV)
KROS
NASDAQ
Keros Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$11.16
+11.27% 1D
Market Cap
$202.1M
1M Return
+0.9%
1Y Return
-35.34%
Forward P/E
48.8x
Unified AI Score
52.2 / 100
HOLD
Tech 55.0
Fund 64.0
Flow 67.0
Mom 50.0
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
KROS -35.34%
LYRA -94.34%
Spread: +51.04 pp (KROS Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | KROS Revenue | LYRA Revenue | KROS Op. Margin | LYRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -105.6% | N/A | KROS |
| FY2021 | $20M | $0M | -280.5% | -15303.5% | KROS |
| FY2022 | N/A | $0M | N/A | -4131.0% | LYRA |
| FY2023 | $0M | $0M | -112543.7% | -4308.1% | LYRA |
| FY2024 | $0M | $0M | -5939.0% | -6280.8% | KROS |
| FY2025 | $240M | $0M | 27.7% | -7794.5% | KROS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | KROS | LYRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $202.1M | $2.3M | Larger Scale | KROS |
| Trailing P/E Ratio Valuation | 48.8x | N/M | Lower Multiple | KROS |
| Forward P/E Ratio Valuation | 48.8x | N/M | Lower Multiple | KROS |
| Revenue Growth (YoY) Growth | +180.5% | -87.2% | Higher Growth | KROS |
| Operating Margin (TTM) Profitability | -172.4% | -25032.0% | Higher Margin | KROS |
| Net Profit Margin Profitability | -151.4% | 0.0% | Higher Margin | LYRA |
| Return on Equity (ROE) Capital Efficiency | -12.6% | -404.5% | Higher ROE | KROS |
| 52-Week Range Position Momentum | 16% ($9โ$23) | 1% ($0โ$38) | Stronger Trend | KROS |
| Beta / 30D Volatility Risk Regime | 1.11ฮฒ ยท 67% Vol | 0.33ฮฒ ยท 248% Vol | Lower Realized Risk | KROS |
| Unified Institutional Score Composite Signal | 52.2 / 100 (HOLD) | 52.2 / 100 (HOLD) | Higher Composite | Tie |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full KROS vs LYRA Buy Guide
KROS
CONSOLIDATION
92d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
10th %ile
IV Regime
Compressed (<25th %ile)
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither KROS nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.